Drug Trial Radar · NCT01498822
Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy
Last checked: Nov 19, 2026Latest source record: Aug 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
353
Actual
Start
Jun 2011
Primary completion
Jul 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- Korea UCB Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the long term effectiveness of Levetiracetam (LEV) monotherapy on Treatment Failure Rate in subjects with newly diagnosed partial onset seizures with or without secondary generalized seizures, compared to Oxcarbazepine (OXC) monotherapy over 50 weeks from the first dose
Conditions
- Epilepsy
Interventions
LevetiracetamDrug
250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
OxcarbazepineDrug
150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With a Treatment FailureTime frame: Week 0 (First Dose) to Week 50
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
05
Busan, South Korea
10
Busan, South Korea
16
Busan, South Korea
06
Daejeon, South Korea
18
Daejeon, South Korea
23
Gangwon-Do, South Korea
08
Goyang-si, South Korea
09
Goyang-si, South Korea
07
Gwangju, South Korea
22
Junggu, South Korea
14
Seongnam-si, South Korea
01
Seoul, South Korea
02
Seoul, South Korea
03
Seoul, South Korea
04
Seoul, South Korea
11
Seoul, South Korea
12
Seoul, South Korea
13
Seoul, South Korea
15
Seoul, South Korea
17
Seoul, South Korea
20
Seoul, South Korea
21
Seoul, South Korea
19
Ulsan, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.